Shanghai - Delayed Quote CNY
Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS)
4.4100
+0.0100
+(0.23%)
At close: 3:00:04 PM GMT+8
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
6,375,736.6606
6,515,163.4354
6,732,797.0371
6,000,443.3937
6,568,185.3419
Cost of Revenue
3,029,900.8958
3,052,721.2909
2,795,598.4389
2,442,449.1769
2,548,287.8819
Gross Profit
3,345,835.7648
3,462,442.1445
3,937,198.5982
3,557,994.2168
4,019,897.4599
Operating Expense
2,690,139.3773
2,748,206.5033
3,091,911.4231
2,772,599.0302
3,140,625.5408
Operating Income
655,696.3874
714,235.6412
845,287.1751
785,395.1867
879,271.9191
Net Non Operating Interest Income Expense
7,340.1878
13,892.0029
15,581.6281
4,994.7430
-59,475.3071
Pretax Income
735,527.2683
779,941.6940
767,690.6325
590,009.3298
2,526,894.9467
Tax Provision
114,116.3427
121,586.8211
92,967.0346
129,891.4545
391,125.9690
Net Income Common Stockholders
595,749.8702
622,417.0293
591,572.9417
358,119.4185
2,017,463.2064
Basic EPS
0.24
0.25
0.23
0.14
0.78
Diluted EPS
0.23
0.25
0.23
0.14
0.78
Basic Average Shares
2,477,942.9380
2,489,668.1170
2,572,056.2680
2,557,995.8460
2,586,491.2900
Diluted Average Shares
2,586,450.9630
2,489,668.1170
2,572,056.2680
2,557,995.8460
2,586,491.2900
Total Operating Income as Reported
757,222.9769
798,885.3069
788,265.9001
602,462.2892
2,534,531.4936
Total Expenses
5,720,040.2731
5,800,927.7942
5,887,509.8620
5,215,048.2071
5,688,913.4228
Net Income from Continuing & Discontinued Operation
595,749.8702
622,417.0293
591,572.9417
358,119.4185
2,017,463.2064
Normalized Income
577,654.3878
622,962.7859
730,395.9080
538,258.5827
2,762,428.4604
Interest Income
24,036.9396
35,737.2170
53,013.4379
55,572.2928
14,730.0817
Interest Expense
14,929.5015
20,785.6449
36,402.0679
49,471.6489
72,973.2120
Net Interest Income
7,340.1878
13,892.0029
15,581.6281
4,994.7430
-59,475.3071
EBIT
750,456.7697
800,727.3389
804,092.7004
639,480.9786
2,599,868.1587
EBITDA
750,456.7697
1,145,670.2267
1,128,441.9600
916,964.2258
2,886,551.2704
Reconciled Cost of Revenue
3,029,900.8958
3,052,721.2909
2,795,598.4389
2,442,449.1769
2,548,287.8819
Reconciled Depreciation
--
344,942.8878
324,349.2596
277,483.2471
286,683.1117
Net Income from Continuing Operation Net Minority Interest
595,749.8702
622,417.0293
591,572.9417
358,119.4185
2,017,463.2064
Total Unusual Items Excluding Goodwill
21,418.5496
-646.5486
-157,950.7388
-230,992.5201
-881,391.6465
Total Unusual Items
21,418.5496
-646.5486
-157,950.7388
-230,992.5201
-881,391.6465
Normalized EBITDA
729,038.2201
1,146,316.7753
1,286,392.6988
1,147,956.7459
3,767,942.9168
Tax Rate for Calcs
0.0002
0.0002
0.0001
0.0002
0.0002
Tax Effect of Unusual Items
3,323.0672
-100.7919
-19,127.7725
-50,853.3559
-136,426.3925
12/31/2021 - 4/12/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade